Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating t… Read more
Alar Pharmaceuticals Inc. (6785) - Net Assets
Latest net assets as of June 2024: NT$2.48 Billion TWD
Based on the latest financial reports, Alar Pharmaceuticals Inc. (6785) has net assets worth NT$2.48 Billion TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.55 Billion) and total liabilities (NT$69.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.48 Billion |
| % of Total Assets | 97.29% |
| Annual Growth Rate | 14.45% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.57 |
Alar Pharmaceuticals Inc. - Net Assets Trend (2020–2023)
This chart illustrates how Alar Pharmaceuticals Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alar Pharmaceuticals Inc. (2020–2023)
The table below shows the annual net assets of Alar Pharmaceuticals Inc. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$897.12 Million | +74.37% |
| 2022-12-31 | NT$514.50 Million | -3.72% |
| 2021-12-31 | NT$534.37 Million | -10.73% |
| 2020-12-31 | NT$598.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alar Pharmaceuticals Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 72255600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$327.12 Million | 36.46% |
| Common Stock | NT$570.00 Million | 63.54% |
| Total Equity | NT$897.12 Million | 100.00% |
Alar Pharmaceuticals Inc. Competitors by Market Cap
The table below lists competitors of Alar Pharmaceuticals Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Xinning Modern Logist
SHE:300013
|
$231.22 Million |
|
Andes Technology Corp
TW:6533
|
$231.27 Million |
|
Comp SA
WAR:CMP
|
$231.31 Million |
|
BAF Viet Nam Agriculture JSC
VN:BAF
|
$231.33 Million |
|
Guangzheng Group Co Ltd
SHE:002524
|
$231.22 Million |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
$231.22 Million |
|
Nanjing Port Co Ltd
SHE:002040
|
$231.18 Million |
|
Norwood Financial Corp
NASDAQ:NWFL
|
$231.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alar Pharmaceuticals Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 514,501,000 to 897,117,000, a change of 382,616,000 (74.4%).
- Net income of 382,616,000 contributed positively to equity growth.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$382.62 Million | +42.65% |
| Total Change | NT$- | 74.37% |
Book Value vs Market Value Analysis
This analysis compares Alar Pharmaceuticals Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.80x to 12.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$11.99 | NT$201.50 | x |
| 2021-12-31 | NT$9.37 | NT$201.50 | x |
| 2022-12-31 | NT$9.03 | NT$201.50 | x |
| 2023-12-31 | NT$15.72 | NT$201.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alar Pharmaceuticals Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 42.65%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 81.53%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.08x
- Recent ROE (42.65%) is above the historical average (0.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -23.86% | -23799.50% | 0.00x | 1.01x | NT$-202.66 Million |
| 2021 | -12.02% | 0.00% | 0.00x | 1.01x | NT$-117.67 Million |
| 2022 | -3.86% | -2483.88% | 0.00x | 1.02x | NT$-71.32 Million |
| 2023 | 42.65% | 81.53% | 0.48x | 1.08x | NT$292.90 Million |
Industry Comparison
This section compares Alar Pharmaceuticals Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,317,013,700
- Average return on equity (ROE) among peers: 4.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alar Pharmaceuticals Inc. (6785) | NT$2.48 Billion | -23.86% | 0.03x | $231.22 Million |
| Grape King Bio Ltd (1707) | $2.08 Billion | 18.27% | 0.54x | $415.70 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $4.20 Billion | 8.11% | 0.48x | $159.99 Million |
| Maywufa Co Ltd (1731) | $1.41 Billion | 2.15% | 1.10x | $41.61 Million |
| Allied Biotech Corporation (1780) | $1.08 Billion | 1.21% | 1.26x | $48.27 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.36 Billion | 2.77% | 0.13x | $179.96 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $23.77 Million |
| Easywell Biomedicals Inc. (1799) | $623.80 Million | -23.22% | 0.95x | $82.61 Million |
| LIWANLI Innovation Co Ltd (3054) | $897.52 Million | 5.08% | 0.06x | $51.25 Million |
| YungShin Global Holding Corp (3705) | $5.90 Billion | 12.21% | 0.47x | $295.98 Million |
| TTY Biopharm Co Ltd (4105) | $6.23 Billion | 17.56% | 0.54x | $484.94 Million |